Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 4 | 2019 | 100 | 1.360 |
Why?
|
| Fracture Fixation, Intramedullary | 3 | 2022 | 33 | 1.250 |
Why?
|
| Limb Salvage | 2 | 2020 | 39 | 0.890 |
Why?
|
| Fractures, Spontaneous | 1 | 2022 | 7 | 0.870 |
Why?
|
| Orthopedics | 6 | 2022 | 88 | 0.840 |
Why?
|
| Knee Injuries | 2 | 2019 | 31 | 0.780 |
Why?
|
| Osteosarcoma | 1 | 2019 | 35 | 0.700 |
Why?
|
| Salvage Therapy | 1 | 2019 | 82 | 0.690 |
Why?
|
| Soft Tissue Injuries | 1 | 2017 | 8 | 0.630 |
Why?
|
| Surgical Flaps | 1 | 2017 | 120 | 0.580 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2017 | 146 | 0.510 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2014 | 18 | 0.510 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2014 | 28 | 0.510 |
Why?
|
| Internship and Residency | 4 | 2022 | 596 | 0.490 |
Why?
|
| Hand | 1 | 2014 | 90 | 0.490 |
Why?
|
| Muscle, Skeletal | 1 | 2017 | 396 | 0.490 |
Why?
|
| Chondrosarcoma | 1 | 2014 | 7 | 0.490 |
Why?
|
| Femoral Fractures | 2 | 2013 | 45 | 0.490 |
Why?
|
| Fracture Fixation, Internal | 2 | 2015 | 68 | 0.470 |
Why?
|
| Prosthesis-Related Infections | 1 | 2013 | 70 | 0.430 |
Why?
|
| Organ Transplantation | 1 | 2013 | 110 | 0.400 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2013 | 130 | 0.390 |
Why?
|
| Shoulder Fractures | 1 | 2009 | 5 | 0.370 |
Why?
|
| Orthopedic Procedures | 2 | 2022 | 102 | 0.360 |
Why?
|
| Bone Plates | 1 | 2009 | 49 | 0.350 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 624 | 0.350 |
Why?
|
| Postoperative Complications | 5 | 2022 | 1615 | 0.340 |
Why?
|
| General Surgery | 2 | 2020 | 95 | 0.340 |
Why?
|
| Sarcoma | 3 | 2021 | 70 | 0.330 |
Why?
|
| Retrospective Studies | 8 | 2022 | 7264 | 0.300 |
Why?
|
| Humans | 24 | 2022 | 68525 | 0.270 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 3256 | 0.260 |
Why?
|
| Bone Nails | 2 | 2022 | 32 | 0.240 |
Why?
|
| Clinical Competence | 3 | 2021 | 657 | 0.240 |
Why?
|
| Treatment Outcome | 5 | 2022 | 7028 | 0.230 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2021 | 503 | 0.220 |
Why?
|
| Lower Extremity | 2 | 2021 | 153 | 0.220 |
Why?
|
| Needlestick Injuries | 1 | 2022 | 10 | 0.210 |
Why?
|
| Prognosis | 2 | 2019 | 2093 | 0.200 |
Why?
|
| Rhabdoid Tumor | 1 | 2021 | 9 | 0.200 |
Why?
|
| Infratentorial Neoplasms | 1 | 2021 | 7 | 0.200 |
Why?
|
| Soft Tissue Infections | 1 | 2020 | 19 | 0.190 |
Why?
|
| Anterior Cruciate Ligament Reconstruction | 1 | 2021 | 28 | 0.190 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 61 | 0.190 |
Why?
|
| Workplace Violence | 1 | 2020 | 8 | 0.190 |
Why?
|
| Male | 12 | 2021 | 37281 | 0.180 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 206 | 0.180 |
Why?
|
| Middle Aged | 7 | 2020 | 21119 | 0.170 |
Why?
|
| Propensity Score | 1 | 2019 | 116 | 0.170 |
Why?
|
| Ischemia | 1 | 2020 | 229 | 0.170 |
Why?
|
| Patellar Ligament | 1 | 2019 | 3 | 0.170 |
Why?
|
| SEER Program | 1 | 2019 | 150 | 0.170 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 595 | 0.170 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 91 | 0.160 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2019 | 99 | 0.160 |
Why?
|
| Adult | 8 | 2020 | 21375 | 0.160 |
Why?
|
| Adolescent | 4 | 2021 | 8903 | 0.160 |
Why?
|
| Child | 3 | 2021 | 6400 | 0.150 |
Why?
|
| Aged | 5 | 2020 | 14842 | 0.150 |
Why?
|
| Teaching | 1 | 2019 | 169 | 0.150 |
Why?
|
| Radiation Protection | 1 | 2018 | 71 | 0.150 |
Why?
|
| Young Adult | 3 | 2020 | 5708 | 0.150 |
Why?
|
| Learning | 1 | 2019 | 186 | 0.150 |
Why?
|
| Occupational Exposure | 1 | 2018 | 122 | 0.150 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 4843 | 0.150 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 371 | 0.150 |
Why?
|
| Perioperative Care | 1 | 2017 | 100 | 0.150 |
Why?
|
| Radiation Exposure | 1 | 2018 | 84 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 265 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 378 | 0.140 |
Why?
|
| Survival Rate | 1 | 2019 | 1055 | 0.140 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 375 | 0.140 |
Why?
|
| Infant | 2 | 2021 | 2891 | 0.140 |
Why?
|
| Patient Readmission | 1 | 2019 | 267 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 498 | 0.130 |
Why?
|
| Female | 9 | 2020 | 38015 | 0.130 |
Why?
|
| Acetabulum | 1 | 2015 | 20 | 0.130 |
Why?
|
| Ossification, Heterotopic | 1 | 2015 | 45 | 0.130 |
Why?
|
| Physicians | 1 | 2018 | 324 | 0.120 |
Why?
|
| Fractures, Bone | 1 | 2015 | 132 | 0.120 |
Why?
|
| X-Rays | 1 | 2014 | 56 | 0.120 |
Why?
|
| Mitochondria | 1 | 2019 | 643 | 0.120 |
Why?
|
| Infant, Newborn | 1 | 2019 | 2453 | 0.120 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 201 | 0.110 |
Why?
|
| Femur | 1 | 2014 | 113 | 0.110 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2013 | 4 | 0.110 |
Why?
|
| Fractures, Stress | 1 | 2013 | 12 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 306 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2015 | 383 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2019 | 3185 | 0.110 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2012 | 53 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 766 | 0.100 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 799 | 0.100 |
Why?
|
| Neoplasms | 1 | 2022 | 1660 | 0.100 |
Why?
|
| Reoperation | 1 | 2013 | 467 | 0.100 |
Why?
|
| Recurrence | 1 | 2014 | 948 | 0.100 |
Why?
|
| Femoral Neoplasms | 1 | 2010 | 7 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2012 | 258 | 0.100 |
Why?
|
| United States | 4 | 2021 | 7335 | 0.100 |
Why?
|
| Debridement | 1 | 2010 | 55 | 0.100 |
Why?
|
| Workplace | 2 | 2022 | 75 | 0.100 |
Why?
|
| Therapeutic Irrigation | 1 | 2010 | 63 | 0.100 |
Why?
|
| Sheep | 1 | 2010 | 128 | 0.090 |
Why?
|
| Smoking | 1 | 2019 | 1449 | 0.090 |
Why?
|
| Pressure | 1 | 2010 | 252 | 0.090 |
Why?
|
| Fracture Healing | 1 | 2009 | 29 | 0.090 |
Why?
|
| Equipment Design | 1 | 2010 | 500 | 0.090 |
Why?
|
| Immunotherapy | 2 | 2022 | 212 | 0.090 |
Why?
|
| Time Factors | 2 | 2019 | 4655 | 0.080 |
Why?
|
| Age Factors | 1 | 2014 | 1860 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2010 | 714 | 0.080 |
Why?
|
| Risk Factors | 3 | 2019 | 5719 | 0.080 |
Why?
|
| Incidence | 1 | 2013 | 1582 | 0.080 |
Why?
|
| Prosthesis Design | 1 | 2009 | 301 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 2798 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2015 | 3702 | 0.070 |
Why?
|
| Animals | 4 | 2022 | 20877 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 1026 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 1172 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2323 | 0.060 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2022 | 17 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 69 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 211 | 0.050 |
Why?
|
| SMARCB1 Protein | 1 | 2021 | 4 | 0.050 |
Why?
|
| Operative Time | 1 | 2021 | 45 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2020 | 52 | 0.050 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2020 | 50 | 0.050 |
Why?
|
| Risk | 1 | 2020 | 563 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 61 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2021 | 214 | 0.040 |
Why?
|
| Mice | 2 | 2022 | 8472 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2019 | 75 | 0.040 |
Why?
|
| eIF-2 Kinase | 1 | 2019 | 49 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2021 | 145 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2019 | 117 | 0.040 |
Why?
|
| Atherosclerosis | 1 | 2020 | 204 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 86 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 1 | 2019 | 148 | 0.040 |
Why?
|
| Operating Rooms | 1 | 2019 | 108 | 0.040 |
Why?
|
| Research | 1 | 2019 | 214 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 508 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 737 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 499 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 621 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 1046 | 0.030 |
Why?
|
| Mutation | 1 | 2021 | 1213 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1419 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2019 | 413 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 2356 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1425 | 0.030 |
Why?
|
| Job Satisfaction | 1 | 2014 | 62 | 0.030 |
Why?
|
| Tobacco Use Disorder | 1 | 2019 | 432 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 572 | 0.030 |
Why?
|
| Osteomalacia | 1 | 2013 | 8 | 0.030 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2013 | 15 | 0.030 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2012 | 8 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 880 | 0.030 |
Why?
|
| Sarcoma, Synovial | 1 | 2012 | 11 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2012 | 63 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 2012 | 36 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2012 | 124 | 0.030 |
Why?
|
| Markov Chains | 1 | 2012 | 133 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 274 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 1085 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1548 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2012 | 303 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2019 | 1032 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 2688 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 2222 | 0.010 |
Why?
|